In Table 1, we present a summary of the currently available, placebo-controlled, and active-controlled RCTs that evaluated agents with GLP-1 receptor agonists’ activity to treat MASLD or MASH. Here, GLP1R is linked to metabolic dysfunction-associated steatohepatitis.